No hiding place for AstraZeneca as Mystic fears materialize

27 July 2017
astrazeneca-large

Investors have been speculating for months what the outcome of AstraZeneca’s (LSE: AZN) Mystic lung cancer trial might be, seeking to find clues in every word spoken by company executives and researchers.

Did the fact that, in recent weeks in particular, the Anglo-Swedish company has sought to stress that this summer’s data read-out is just of the progression-free survival (PFS) figures, not the overall survival (OS) assessment that the trial was designed to evaluate, indicate that the initial results would not be positive? Did uncertainty around chief executive Pascal Soriot suggest something? Were rumors of a takeover an indication?

Whether these developments provided a hint or not, a fact that investors and Mr Soriot accepted was that if this summer’s Mystic results were bad, then it would have a significant impact on the company’s share price.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical